Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.57 |
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | WNT3A | P56704 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583031 | 0.81 | MCHR1 (0.50) | MCHR1HTR2C | |
| SCHEMBL5582926 | 0.81 | HTR2C (0.52) | MCHR1HTR2C | |
| SCHEMBL5582877 | 0.77 | MCHR1 (0.59) | MCHR1HTR2C | |
| SCHEMBL2927690 | 0.73 | MCHR1 (0.82) | MCHR1HTR2CABL1KITABL2 | |
| SCHEMBL5645431 | 0.73 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL5647747 | 0.72 | MCHR1 (0.98) | MCHR1HTR2C | |
| SCHEMBL5934306 | 0.72 | NPC1 (0.65) | MCHR1HTR2C | |
| SCHEMBL5934378 | 0.72 | RAB9A (0.72) | — | |
| SCHEMBL2924504 | 0.71 | MCHR1 (0.75) | MCHR1HTR2CWNT3A | |
| SCHEMBL5934282 | 0.71 | P4HTM (0.56) | MCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885WNT3A 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.